Is NEOG a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Recurring food safety testing demand, with revenue (fy2026 guidance) at ~$857-860M. The bear case rests on integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. Analysts covering it are spread from $11.00 to $13.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $11.00, +20.9% from the $9.10 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Recurring food safety testing demand. Food Safety is now roughly 70% of revenue and grew mid-single digits in core terms in recent quarters. The most optimistic analyst target on NEOG is $13.00, +42.9% from the $9.10 price. That figure is only reachable if this thesis works close to its best case.

Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. The company carries elevated leverage and competes against larger, better-capitalized players in both food and animal diagnostics. Core revenue in the Animal Safety segment declined in recent quarters, showing uneven demand. The genomics divestiture removes a ~$90 million revenue line, so the remaining business must carry growth on its own. The stock has been volatile and traded near multi-year lows, so sentiment can swing sharply on quarterly execution. The most pessimistic published target is $11.00, +20.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Neogen Corporation, based in Lansing, Michigan and incorporated in 1981, develops and markets diagnostic products and test kits that detect contamination in the food chain and supp

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Recurring food safety testing demand) stalling in the reported numbers rather than in the narrative, the risk above (integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Neogen develops and sells diagnostic test kits and products for food safety and animal safety, detecting pathogens, toxins, allergens, and contaminants in the food chain and supporting animal health with veterinary instruments, disinfectants, and reagents.

It reports two segments: Food Safety, which is roughly 70% of revenue after the 3M acquisition and tests food and feed for contaminants, and Animal Safety, which sells veterinary and animal-care products, diagnostics, and pest control items.

The stock has been pressured by a difficult, costly integration of the acquired 3M Food Safety business, elevated debt, reported GAAP net losses from acquisition amortization, and uneven core growth, which pushed shares toward multi-year lows.